{
    "title": "Amylyx prices newly approved ALS drug at $158,000 per year",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11267033/Amylyx-prices-newly-approved-ALS-drug-158-000-year.html",
    "date": "2022-09-30",
    "keywords": [
        "drug",
        "price",
        "leo",
        "year",
        "relyvrio",
        "officer",
        "olinger",
        "cost",
        "rind",
        "klee",
        "cohen",
        "challenge",
        "friday",
        "sclerosis",
        "discount",
        "competitor",
        "food",
        "administration",
        "treatment",
        "firm",
        "riluzole",
        "amylyx",
        "prescription",
        "conference",
        "company",
        "production",
        "proof",
        "efficacy",
        "pricing",
        "watchdog",
        "institute",
        "review",
        "manufacturer",
        "situation",
        "obligation",
        "top",
        "range",
        "trial",
        "europe",
        "cochief",
        "executive",
        "joshua",
        "interview",
        "research",
        "paralysis",
        "death",
        "ice",
        "bucket",
        "approval",
        "advocacy",
        "group",
        "raise",
        "reporting",
        "roy",
        "bengaluru",
        "editing",
        "chandra",
        "eluri"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}